全文获取类型
收费全文 | 4520篇 |
免费 | 604篇 |
国内免费 | 182篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 51篇 |
妇产科学 | 53篇 |
基础医学 | 974篇 |
口腔科学 | 75篇 |
临床医学 | 263篇 |
内科学 | 908篇 |
皮肤病学 | 61篇 |
神经病学 | 387篇 |
特种医学 | 52篇 |
外国民族医学 | 1篇 |
外科学 | 261篇 |
综合类 | 302篇 |
现状与发展 | 3篇 |
预防医学 | 154篇 |
眼科学 | 32篇 |
药学 | 453篇 |
2篇 | |
中国医学 | 145篇 |
肿瘤学 | 1109篇 |
出版年
2024年 | 14篇 |
2023年 | 301篇 |
2022年 | 295篇 |
2021年 | 432篇 |
2020年 | 385篇 |
2019年 | 239篇 |
2018年 | 242篇 |
2017年 | 223篇 |
2016年 | 215篇 |
2015年 | 288篇 |
2014年 | 346篇 |
2013年 | 385篇 |
2012年 | 192篇 |
2011年 | 235篇 |
2010年 | 168篇 |
2009年 | 182篇 |
2008年 | 151篇 |
2007年 | 156篇 |
2006年 | 106篇 |
2005年 | 105篇 |
2004年 | 52篇 |
2003年 | 68篇 |
2002年 | 44篇 |
2001年 | 53篇 |
2000年 | 34篇 |
1999年 | 32篇 |
1998年 | 21篇 |
1997年 | 26篇 |
1996年 | 24篇 |
1995年 | 24篇 |
1994年 | 25篇 |
1993年 | 19篇 |
1992年 | 20篇 |
1991年 | 24篇 |
1990年 | 18篇 |
1989年 | 25篇 |
1988年 | 12篇 |
1987年 | 7篇 |
1986年 | 16篇 |
1985年 | 16篇 |
1984年 | 11篇 |
1983年 | 16篇 |
1982年 | 11篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1976年 | 2篇 |
1974年 | 4篇 |
1971年 | 2篇 |
排序方式: 共有5306条查询结果,搜索用时 15 毫秒
1.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
2.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献
3.
4.
目的 通过观察黄芩苷对乳腺癌组织毛细血管通透性(Capillary Vessel Permeability,CVP)、赖氨酰氧化酶(Lysyl Oxidase,LOX)及血清丙二醛(Malondialdehyde,MDA)等相关指标的影响,探讨黄芩苷可能的抗乳腺癌作用机制。方法 通过在裸鼠皮下接种MDA-MB-231乳腺癌细胞株建立乳腺癌移植瘤模型;实验分为模型组、黄芩苷组、阿霉素组、黄芩苷+阿霉素组。于接种第7日开始:黄芩苷组每天灌胃黄芩苷水溶液(100 mg·kg-1),连续14天;阿霉素组每3天腹腔注射一次阿霉素(5mg·kg-1),共用药5次;模型组每天灌胃生理盐水(10 mL·kg-1),连续14天;黄芩苷+阿霉素组每天灌胃黄芩苷水溶液(100 mg·kg-1),连续14天,并每3天腹腔注射一次阿霉素5 mg·kg-1,共5次。给药期间监测移植瘤体积;紫外可见分光光度计620 nm下测OD值来反映黄芩苷对肿瘤毛细血管通透性的影响;硫代巴比妥酸(Thiobarbituric acid,TBA)比色法检测黄芩苷对裸鼠血清中丙二醛(MDA)的影响;免疫组化染色法检测乳腺癌组织中赖氨酰氧化酶(LOX)的表达情况。结果 ①与模型组比较,黄芩苷组、阿霉素组、黄芩苷+阿霉素组瘤体重量均明显减轻(P<0.05);黄芩苷+阿霉素组瘤体重量较阿霉素组明显减轻(P<0.05)。②与模型组比较,黄芩苷组降低乳腺癌组织毛细血管的通透性,而阿霉素组则增加肿瘤组织中毛细血管的通透性,差异均具有统计学意义(P<0.05)。③黄芩苷组能够明显抑制荷瘤裸鼠血清MDA的表达,与模型组比较差异有显著统计学意义(P<0.01);阿霉素组促进MDA的表达,与模型组比较差异有统计学意义;黄芩苷+阿霉素组促进MDA的表达,与模型组比较差异无统计学意义。④与模型组比较,黄芩苷组裸鼠乳腺癌组织LOX的表达显著下调(P<0.01),阿霉素组肿瘤组织中LOX表达增加(P<0.05);黄芩苷+阿霉素组能下调裸鼠乳腺癌组织LOX的表达,与模型组比较差异无统计学意义。结论 黄芩苷能够明显抑制乳腺癌移植瘤的生长,其机制可能与黄芩苷降低肿瘤组织毛细血管的通透性,抑制裸鼠血清中丙二醛、乳腺癌组织中赖氨酰氧化酶的表达,从而改变肿瘤缺氧微环境有关。 相似文献
5.
瓦博格效应认为,即便在氧气充足时,肿瘤仍大量利用葡萄糖进行有氧糖酵解,产生乳酸和少量ATP。虽产能效率低,但中间产物有利于改造肿瘤微环境,促进肿瘤恶性进展。近年发现,成纤维细胞作为肿瘤间质的重要组成部分,在肿瘤细胞诱导下具有癌相关成纤维细胞(cancer-associated fibroblast, CAF)表型,通过自身线粒体功能障碍、自噬而持续向肿瘤细胞提供生物大分子合成原料,用以促进肿瘤增殖、侵袭、转移、耐药。相反,肿瘤细胞自身则提高线粒体代谢水平,进行氧化磷酸化,此现象被命名为反瓦博格效应。CAF与酸化的微环境驱动肿瘤细胞自发选择葡萄糖代谢方式、促进肿瘤恶性进展。 相似文献
6.
Tumor tissue is composed of tumor cells and tumor stroma. Tumor stroma contains various immune cells and non-immune stromal cells, forming a complex tumor microenvironment which plays pivotal roles in regulating tumor growth. Recent successes in immunotherapies against tumors, including immune checkpoint inhibitors, have further raised interests in the immune microenvironment of liver carcinoma. The immune microenvironment of tumors is formed because of interactions among tumor cells, immune cells and non-immune stromal cells, including fibroblasts and endothelial cells. Different patterns of immune microenvironment are observed among different tumor subtypes, and their clinicopathological significance and intertumor/intratumor heterogeneity are being intensively studied. Here, we review the immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma, focusing on its histopathological appearance, clinicopathological significance, and relationship with histological and molecular classifications. Understanding the comprehensive histopathological picture of a tumor immune microenvironment, in addition to molecular and genetic approaches, will further potentiate the effort for precision medicine in the era of tumor-targeting immunotherapy. 相似文献
7.
《Journal of thoracic oncology》2021,16(10):1694-1704
IntroductionIn patients with NSCLC, the prognostic significance of the tumor microenvironment (TME) immune composition has been revealed using single- or dual-marker staining on sequential tissue sections. Although these studies reveal that relative abundance and localization of immune cells are important parameters, deeper analyses of the NSCLC TME are necessary to refine the potential application of these findings to clinical care. Currently, the complex spatial relationships between cells of the NSCLC TME and potential drivers contributing to its immunologic composition remain unknown.MethodsWe used multispectral quantitative imaging on the lung adenocarcinoma TME in 153 patients with resected tumors. On a single slide per patient, we evaluated the TME with markers for CD3, CD8, CD14, CD19, major histocompatibility complex II (MHCII), cytokeratin, and 4′,6-diamidino-2-phenylindole (DAPI). Image analysis, including tissue segmentation, phenotyping, and spatial localization, was performed.ResultsSpecimens wherein greater than or equal to 5% of lung cancer cells expressed MHCII (MHCIIhi TME) had increased levels of CD4+ and CD8+ T cells and CD14+ cell infiltration. In the MHCIIhi TME, the immune infiltrate was closer to cancer cells and expressed an activated phenotype. Morphologic image analysis revealed cancer cells in the MHCIIhi TME more frequently interfaced with CD4+ and CD8+ T cells. Patients with an MHCIIhi TME experienced improved overall survival (p = 0.046).ConclusionsLung cancer cell-specific expression of MHCII associates with levels of immune cell infiltration, spatial localization, and activation status within the TME. This suggests that cancer cell-specific expression of MHCII may represent a biomarker for the immune system’s recognition and activation against the tumor. 相似文献
8.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
9.
10.
《Vaccine》2019,37(31):4382-4391
Cancer-associated fibroblasts (CAFs), major components of the tumor microenvironment (TME), promote tumor growth and metastasis and inhibit the anti-tumor immune response. We previously constructed a DNA vaccine expressing human FAPα, which is highly expressed by CAFs, to target these cells in the TME, and observed limited anti-tumor effects in the 4T1 breast cancer model. When the treatment time was delayed until tumor nodes formed, the anti-tumor effect of the vaccine completely disappeared. In this study, to improve the safety and efficacy, we constructed a new FAPα-targeted vaccine containing only the extracellular domain of human FAPα with a tissue plasminogen activator signal sequence for enhanced antigen secretion and immunogenicity. The number of CAFs was more effectively reduced by CD8+ T cells induced by the new vaccine. This resulted in decreases in CCL2 and CXCL12 expression, leading to a significant decrease in the ratio of myeloid-derived suppressor cells in the TME. Moreover, when mice were treated after the establishment of tumors, the vaccine could still delay tumor growth. To facilitate the future application of the vaccine in clinical trials, we further optimized the gene codons and reduced the homology between the vaccine and the original sequence, which may be convenient for evaluating the vaccine distribution in the human body. These results indicated that the new FAPα-targeted vaccine expressing an optimized secreted human FAPα induced enhanced anti-tumor activity by reducing the number of FAPα+ CAFs and enhancing the recruitment of effector T cells in the 4T1 tumor model mice. 相似文献